Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | KRAS | P01116 | 14/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437918 | 1.00 | GPR119 (0.36) | GPR119KRASJAK1JAK2TYK2 | |
| SCHEMBL30149131 | 1.00 | GPR119 (0.36) | GPR119KRASJAK1JAK2TYK2 | |
| SCHEMBL31493993 | 0.93 | KRAS (0.36) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL30841170 | 0.92 | GPR119 (0.36) | GPR119KRASJAK1JAK2TYK2 | |
| SCHEMBL31669685 | 0.92 | GPR119 (0.36) | GPR119KRASJAK1JAK2TYK2 | |
| SCHEMBL31048829 | 0.92 | KRAS (0.37) | GPR119KRASJAK1JAK2TYK2 | |
| SCHEMBL30260027 | 0.91 | KRAS (0.36) | KRASJAK1JAK2TYK2JAK3 | |
| SCHEMBL30910344 | 0.91 | GPR119 (0.36) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL30910345 | 0.91 | GPR119 (0.36) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL30801094 | 0.91 | KRAS (0.39) | GPR119KRASJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025072686-A1 | KRAS G12D MUTATION TARGETING COMPOUNDS | SUMMIT THERAPEUTICS INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240293558-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024044334-A2 | METHODS AND COMPOSITIONS FOR MODULATING KRAS(G12D) | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | GPR119 3564/4885KRAS 2/4885JAK1 2559/4885 |
| US-20240293558-A1 | KRAS INHIBITOR CONJUGATES | KRAS, MDM2, NRAS | GPR119 3086/4885KRAS 1/4885JAK1 3634/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | GPR119 3746/4885KRAS 1/4885JAK1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.